-2-

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

7346222928

(currently amended) A compound of formula (Ia): 1.

$$\mathbb{R}^{1}$$
 $\mathbb{R}^{4}$ 
 $\mathbb{R}^{3}$ 
 $\mathbb{R}^{3}$ 

or a pharmaceutically acceptable salt, hydrate, tautomer or solvate thereof, wherein:

X is O or S;

R<sup>1</sup> is selected from the group consisting of

PATENT PFIZER ANN ARBOR MI

where  $R^{2a}$  is independently selected from the group consisting of:  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_3-C_{10})$ cycloalkyl,  $(C_5-C_{10})$ aryl,  $(C_1-C_6)$ alkylaryl, amino, carbonyl, carboxyl,  $(C_5-C_{10})$ heteroaryl,

(C<sub>5</sub>-C<sub>10</sub>)heterocyclyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, nitro, halo, hydroxyl, and (C<sub>1</sub>-C<sub>6</sub>)alkoxy(C<sub>1</sub>-C<sub>6</sub>)ester, and where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, amino, heteroaryl, heterocyclyl, and alkoxy of  $R^{2a}$  is optionally substituted by at least one moiety independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, formyl, NC-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-,

Feb-02-2007 11:09am

phenyl-(C=O)-, HO-(C=O)-, ( $C_1$ - $C_6$ )alkyl-O-(C=O)-, ( $C_1$ - $C_6$ )alkyl-NH-(C=O)-, (( $C_1$ - $C_6$ )alkyl)<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl- $[((C_1-C_6)alkyl)-N]-(C=O)-$ ,  $Q_2N-$ , amino,  $(C_1-C_6)alkyl)-N$  $C_6$ )alkylamino, (( $C_1$ - $C_6$ )alkyl)<sub>2</sub>-amino, ( $C_1$ - $C_6$ )alkyl-(C=O)-NH-, ( $C_1$ - $C_6$ )alkyl-(C=O)-[(( $C_1$ - $C_6$ )alkyl-(C=O)-[((C-C)-[((C $C_6$ )alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(( $C_1$ - $C_6$ )alkyl)-N]-,  $H_2$ N-(C=O)-NH-, ( $C_1$ - $C_6$ )alkyl)-N]-,  $((C_1-C_6)$ alkyl)<sub>2</sub>N-(C=O)-[ $(C_1-C_6)$ alkyl-N]-, phenyl-HN-(C=O)-NH-, (phenyl)<sub>2</sub>N-(C=O)-NH-, phenyl-HN- $(C=O)-[((C_1-C_6)a!kyl)-N]$ -,  $(phenyl-)_2N-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-O-(C=O)-NH-,$  $(C_1-C_6)alkyl-O-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-O-(C=O)-NH-,$ phenyl-O-(C=O)-[(alkyl)-N]-, ( $C_1$ - $C_6$ )alkyl-SO<sub>2</sub>NH-, phenyl-SO<sub>2</sub>NH-, ( $C_1$ - $C_6$ )alkyl-SO<sub>2</sub>-, phenyl- $SO_2$ -, hydroxy,  $(C_1-C_6)$ alkoxy, perhalo $(C_1-C_6)$ alkoxy, phenoxy,  $(C_1-C_6)$ alkyl-(C=O)-O-,  $(C_1-C_6)$  ester- $(C_1-C_6)$  alkyl-O-, phenyl-(C=O)-O-,  $H_2N$ -(C=O)-O-,  $(C_1-C_6)$  alkyl-HN-(C=O)-O-,  $((C_1-C_6)alkyl)_2N-(C=O)-O-$ , phenyl-HN-(C=O)-O-, and (phenyl)\_2N-(C=O)-O-; wherein R<sup>1</sup> can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo( $C_1$ - $C_6$ )alkyl, perhalo( $C_1$ - $C_6$ )alkoxy, ( $C_1$ - $C_6$ )alkyl, ( $C_2$ - $C_6$ )alkenyl, ( $C_2$ - $C_6$ )alkynyl, hydroxy, oxo, mercapto,  $(C_1-C_6)$ alkylthio,  $(C_1-C_6)$ alkoxy,  $(C_5-C_{10})$ aryl, of  $(C_5-C_{10})$ heteroaryl,  $(C_5-C_{10})$  $C_{10}$ )aryloxy,  $\Theta_T$  ( $C_5$ - $C_{10}$ )heteroaryloxy, ( $C_5$ - $C_{10}$ )ar( $C_1$ - $C_6$ )alkyl,  $\Theta_T$  ( $C_5$ - $C_{10}$ )heteroar( $C_1$ - $C_6$ )alkyl,  $(C_5-C_{10})$ ar $(C_1-C_6)$ alkoxy, ef  $(C_5-C_{10})$ heteroar $(C_1-C_6)$ alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkylamino $(C_1-C_6)$ alkyl, di $(C_1-C_6)$ alkylamino $(C_1-C_6)$ alkyl,  $(C_5-C_{10})$ heterocyclyl $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkyl-, and di $(C_1-C_6)$ alkylamino, cyano, nitro, carbamoyl,  $(C_1-C_6)$ alkylcarbonyl,  $(C_1-C_6)$ alkoxycarbonyl,  $(C_1-C_6)$ alkylcarbonyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, (C<sub>5</sub>-C<sub>10</sub>)arylcarbonyl, (C<sub>5</sub>-C<sub>10</sub>)aryloxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, and (C<sub>5</sub>-C<sub>10</sub>)arylsulfonyl;

each R3 is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl,  $(C_5-C_{10})$ heteroaryl,  $(C_5-C_{10})$ heterocyclic,  $(C_3-C_{10})$ cycloalkyl, hydroxy,  $(C_1-C_6)$ alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>- $C_{10}$ )cycloalkyl-O-, ( $C_1$ - $C_6$ )alkyl-S-, ( $C_1$ - $C_6$ )alkyl-SO<sub>2</sub>-, ( $C_1$ - $C_6$ )alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino. Ph(CH2)1-4HN-, (C1-C6)alkyl HN-, (C1-C6)alkylamino, [(C1-C6)alkyl]2-amino, (C1 $C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]_2-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-;$ 

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of  $\mathbb{R}^3$  is optionally substituted by at least one substituent independently selected from  $(C_1\text{-}C_6)$ alkyl,  $(C_1\text{-}C_6)$ alkoxy, halo $(C_1\text{-}C_6)$ alkyl, halo,  $H_2N$ -,  $Ph(CH_2)_{1-6}HN$ -, and  $(C_1\text{-}C_6)$ alkylHN-;

s is an integer from one to five;

R<sup>4</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylHN-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoO<sub>2</sub>S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N-, phenyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl)-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-; (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of  $\mathbb{R}^4$  is optionally substituted by at least one substituent independently selected from the group consisting of  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, halo $(C_1-C_6)$ alkyl, halo,  $H_2N_-$ ,  $Ph(CH_2)_{1-6}HN_-$ ,  $(C_1-C_6)$ alkyl $HN_-$ ,  $(C_5-C_{10})$ heteroaryl and  $(C_5-C_{10})$ heterocyclyl;

with the proviso that when R<sup>4</sup> is a substituted phenyl moiety, then (a) R<sup>1</sup> is not naphthyl, phenyl or anthracenyl and (b) if R<sup>1</sup> is a phenyl fused with an aromatic or non-aromatic cyclic

-6-

PATENT PFIZER ANN ARBOR MI

ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms independently selected from N, O and S, then the fused cyclic ring of said R<sup>1</sup> moiety is substituted;

with the proviso that when R<sup>4</sup> is NH<sub>2</sub> and X is S, then R<sup>1</sup> is not an amino-substituted pyridyl or pyrimidinyl moiety; and

with the proviso that when in formula (Ia) R4 is CH3 and X is S, R1 is not a 3,4dimethoxy substituted phenyl moiety.

2. (original) A compound of claim 1, wherein R<sup>1</sup> is

3. (original) A compound of claim 1, wherein R1 is

(currently amended) A compound of claim 1, wherein R<sup>1</sup> is 4.

-7-

5. (original) A compound of claim 1, wherein R<sup>1</sup> is

6. (original) A compound of claim 1, wherein R<sup>1</sup> is

7. (original) A compound of claim 1, wherein R<sup>1</sup> is

-8-

(original) A compound of claim 1, wherein R1 is 8.

- 9. (canceled).
- (original) A compound of claim 1, wherein X is S; s is one to two; R3 is hydrogen or 10.  $(C_1-C_6)$ alkyl; and  $R^4$  is H,  $(C_1-C_6)$ alkyl, or amino.
- 11. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12-13. (cancelled)

14. (currently amended) A compound selected from the groups consisting of

2 (5 Benze[1,3]dioxol 5 yl exazel 4 yl) 6 methyl pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-pyridine;

2 (5 Benzo[1,3]dioxol 5 yl oxazol 4 yl) 6 methoxy pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-trifluoromothyl-pyridino;

2 Methyl 5 [4 (6 methyl pyridin 2 yl) exazel 5-yl]-2H-benzetriazele;

4-{4-(6-Methyl pyridin 2-yl) oxazol 5-yl] quinoline;

1-Methyl-6-[4-(6-methyl-pyridin 2-yl) exazel-5-yl] 1H benzotriazole;

6 (4 Pyridin 2 yl oxazol 5 yl) quinoxaline;

6-[4-(6-Mothyl-pyridin-2-yl) exazel 5-yl] quinoxaline;

6-[4-(6-Methyl pyridin 2 yl) exazel 5-yl] quinoline;

6 (4 pyridin 2 yl oxazol 5 yl) quinoline;

- 2-(5-Benzo[1,3]dioxol 5-yl-oxazol-4-yl) 6-ethyl-pyridine;
- 2 (5 Benzo[1,3]dioxol 5 yl oxazol 4 yl) 6 propyl pyridine;
- 6 [4 (6 Methyl pyridin-2-yl) exazel 5 yl] benzethiazele;
- 2-(4-Bonzo[1,3]dioxol-5-yl-oxazol-5-yl)-6-mothyl-pyridine;
- 4-[5-(6-Methyl-pyridin 2-yl) exazel 4-yl] quinoline;
- 1 Methyl 6 [5 (6 methyl pyridin 2 yl) exazel 4 yl] 1H benzetriazole;
- 2 Methyl 5 [5 (6 methyl-pyridin 2 yl) exezel 4-yl] 2H benzotriazole;
- 6-[5-(6-Mothyl-pyridin-2-yl)-oxazol-4-yl]-quinolino;
- 6 [5-(6 Methyl pyridin 2 yl) exazel 4-yl] quinexaline;
- 2 [5 (6 Methyl pyridin 2-yl) exazel 4 yl] [1,5]naphthyridine;
- {4 [5 (6 Methyl pyridin 2 yl) exazel 4 yl] pyridin 2 yl}-phenyl-amine;
- 2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-oxazol-5-yl)-6-methyl pyridine;
- 1 Methyl 6 [2 methyl 5 (6 methyl pyridin 2 yl) exazel-4-yl]-III benzetriazele;
- 2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl) exazel 4-yl] 2H-benzetriazele;
- 6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;
- 6 [2 Methyl 5 (6 methyl pyridin 2 yl) oxazol-4-yl]-quinoxaline;
- 2 [2 Methyl 5 (6 methyl-pyridin-2-yl)-oxazol-4-yl] [1,5]naphthyridine;
- [4 [2 Methyl 5 (6 methyl pyridin 2-yl) exazol-4-yl] pyridin 2-yl} phenyl amine;
- 4-[2-Mothyl-5-(6-mothyl-pyridin 2-yl)-exazel-4-yl] quinoline:
- 4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 4-(3-Methyl-3H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 5-(6-Methyl-pyridin-2-yl)-4-quinolin-6-yl-thiazol-2-ylamine:
- 5-(6-Methyl-pyridin-2-yl)-4-quinoxalin-6-yl-thiazol-2-ylamine;
- 5-(6-Methyl-pyridin-2-yl)-4-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;
- {4 [2-Amino-5-(6-methyl-pyridin-2-yl) thiazel-4-yl] pyridin-2-yl}-phenyl-amine;
- 5-(6-Methyl-pyridin-2-yl)-4-quinolin-4-yl-thiazol-2-ylamine;
- 4-(6-Methyl-pyridin-2-yl)-5-quinolin-6-yl-thiazol-2-ylamine;
- 5-(3-Methyl-3H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 5-(2-Methyl-2H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

-10-

- 5-Benzo[1,3]dioxol-5-yl-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 4-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-thiazol-2-ylamine;
- 4-(6-Methyl-pyridin-2-yl)-5-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;
- {4 [2 Amino 4 (6 methyl pyridin 2 yl) thiazol 5 yl] pyridin 2 yl} phenyl amine;
- 4-(6-Methyl-pyridin-2-yl)-5-quinolin-4-yl-thiazol-2-ylamine;
- 6-[2-Methyl-4 (6 methyl pyridin 2 yl) oxazol 5 yl] quinoline;
- 1 Methyl 6 [2 methyl 4 (6 methyl pyridin 2 yl) oxazol 5 yl] 1H-benzetriazole;
- 2 Methyl 5 [2 methyl 4 (6 methyl pyndin 2 yl) exazel 5 yl] 2H-benzetriazele;
- 2 (5 Benzo[1,3]dioxol 5 yl 2 methyl exazel 4 yl) 6 methyl pyridine;
- 6-[2-Methyl-4-(6-methyl-pyridin-2-yl)-exazol-5-yl]-quinexaline;
- 2 [2 Methyl 4 (6 methyl pyridin 2 yl) exazel 5 yl] [1,5]naphthyridine;
- [4-[2-Methyl-4-(6-methyl-pyridin-2-yl) exazel 5-yl] pyridin 2-yl] phenyl-amine;
- 4 [2 Methyl 4 (6 methyl pyridin 2 yl) exazel 5 yl] quinoline;
- 1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;
- 2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;
- 2-(5-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-6-methyl-pyridine;
- 6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;
- 2-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;
- [4-[4-(6-Methyl-pyridin-2-yl) thiazel-5-yl] pyridin 2-yl] phenyl amine;
- 4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
- 6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
- 1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;
- 2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;
- 2-(4-Benzo[1,3]dioxol-5-yl-thiazol-5-yl)-6-methyl-pyridine;
- 6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;
- 2-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;
- {4 [5 (6 Methyl pyridin 2 yl)-thiazol-4-yl]-pyridin 2 yl} phonyl amine;
- 4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;
- 6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;
- 1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-bonzotriazole;

- 2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;
- 2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-4-yl)-6-methyl-pyridine;
- 6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;
- 2-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;
- 44 [2 methyl 4 (6 Methyl pyridin 2 yl) thiazol 5 yl]-pyridin 2 yl) phenyl amine;
- 4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
- 6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
- 1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;
- 2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;
- 2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-5-yl)-6-methyl-pyridine;
- 6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;
- 2-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;
- {4-[2 methyl 5 (6 Mothyl pyridin 2 yl) thiazol 4 yl] pyridin 2 yl) phonyl amine;
- 4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thia2ol-4-yl]-quinoline; and
- 6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline; or a pharmaceutically acceptable salt thereof.
- 15. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 and a pharmaceutically acceptable carrier.
- 16. (canceled)
- 17. (canceled)
- 18. (currently amended) A compound of formula (Ib):

or a pharmaceutically acceptable salt, hydrate, tautomer or solvate thereof, wherein:

X is S;

 $\mathbb{R}^1$  is selected from the group consisting of

PATENT PFIZER ANN ARBOR MI

where  $R^{2a}$  is independently selected from the group consisting of:  $(C_1-C_6)alkyl$ , (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, (C<sub>5</sub>-C<sub>10</sub>)aryl, (C<sub>1</sub>-C<sub>6</sub>)alkylaryl, amino, carbonyl, carboxyl, (C5-C10)heteroaryl, (C5-C10)heterocyclyl, (C1-C6)alkoxy, nitro, halo, hydroxyl, and (C1-C6)alkoxy(C1-C6)ester, and where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, amino, heteroaryl, heterocyclyl, and alkoxy of R<sup>2a</sup> is optionally substituted by at least one moiety independently selected from the group consisting of halo, (C1-C6)alkyl, (C2-C6)alkenyl,  $(C_2-C_6)$ alkynyl, perhalo $(C_1-C_6)$ alkyl, phenyl,  $(C_3-C_{10})$ cycloalkyl,  $(C_5-C_{10})$ heteroaryl,  $(C_5-C_{10})$ C<sub>10</sub>)heterocyclic, formyl, NC-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>- $C_6$ )alkyl-O-(C=O)-, ( $C_1$ - $C_6$ )alkyl-NH-(C=O)-, (( $C_1$ - $C_6$ )alkyl)2-N-(C=O)-, phenyl-NH-(C=O)-, phenyl- $[((C_1-C_6)alkyl)-N]-(C=O)-$ ,  $O_2N-$ , amino,  $(C_1-C_6)alkylamino$ ,  $((C_1-C_6)alkyl)_2$ -amino,  $(C_1-C_6)$ alkyl-(C=O)-NH-,  $(C_1-C_6)$ alkyl- $(C=O)-[((C_1-C_6)$ alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-,  $H_2N$ -(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-NH-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-NH-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl-((  $C_6) alkyl)_2 N - (C = O) - NH -, (C_1 - C_6) alkyl - HN - (C = O) - [((C_1 - C_6) alkyl) - N] -, ((C_1 - C_6) alkyl) -, ((C_1 - C_6)$  $C_6$ )alkyl)<sub>2</sub>N-(C=O)-[ (C<sub>1</sub>-C<sub>6</sub>)alkyl-N]-, phenyl-HN-(C=O)-NH-, (phenyl)<sub>2</sub>N-(C=O)-NH-, phenyl-HN-(C=O)-[(( $C_1$ - $C_6$ )alkyl)-N]-, (phenyl-)<sub>2</sub>N-(C=O)-[(( $C_1$ - $C_6$ )alkyl)-N]-, ( $C_1$ - $C_6$ )alkyl-O-(C=O)-NH-, ( $C_1$ - $C_6$ )alkyl-O-(C=O)-[(( $C_1$ - $C_6$ )alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(alkyl)-N]-. (C1-C6)alkyl-SO2NH-, phenyl-SO2NH-, (C1-C6)alkyl-SO2-,

US Response to OA.doc

-14-

phenyl-SO<sub>2</sub>-, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-, phenyl-(C=O)-O-, H<sub>2</sub>N-(C=O)-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-HN-(C=O)-O-, ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl)<sub>2</sub>N-(C=O)-O-; wherein R<sup>1</sup> can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, hydroxy, oxo, moreoapte, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>5</sub>-C<sub>10</sub>)aryl<sub>2</sub> er (C<sub>5</sub>-C<sub>10</sub>)heteroaryloxy, (C<sub>5</sub>-C<sub>10</sub>)aryloxy<sub>2</sub> er (C<sub>5</sub>-C<sub>10</sub>)heteroaryloxy, (C<sub>5</sub>-C<sub>10</sub>)aryloxy<sub>3</sub> er (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, er (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>5</sub>-C<sub>10</sub>)aryloxy<sub>3</sub> er (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, di(C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub> mino (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, di(C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>mino (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>minocarbonyl<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl<sub>3</sub>min

each R³ is independently selected from the group consisting of: hydrogen, halo, halo(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, perhalo(C₁-C₆)alkyl, phenyl, (C₅-C₁₀)heteroaryl, (C₅-C₁₀)heterocyclic, (C₃-C₁₀)cycloalkyl, hydroxy, (C₁-C₆)alkoxy, perhalo(C₁-C₆)alkoxy, phenoxy, (C₅-C₁₀)heteroaryl-O-, (C₅-C₁₀)heterocyclic-O-, (C₃-C₁₀)cycloalkyl-O-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-SO₂-, (C₁-C₆)alkyl-NH-SO₂-, O₂N-, NC-, amino, Ph(CH₂)₁-₆HN-, (C₁-C₆)alkyl HN-, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂-amino, (C₁-C₆)alkyl-SO₂-NH-, amino(C=O)-, aminoO₂S-, (C₁-C₆)alkyl-(C=O)-NH-, (C₁-C₆)alkyl-(C=O)-[((C₁-C₆)alkyl)-N]-, (C₁-C₆)alkyl-(C=O)-, phenyl-(C=O)-, (C₅-C₁₀)heterocyclic-(C=O)-, (C₃-C₁₀)cycloalkyl-(C=O)-, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, H2N(C=O)-, (C₁-C₆)alkyl-NH-(C=O)-, [(C₁-C₆)alkyl]₂-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-NH-(C=O)-, (C₃-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)heteroaryl-NH-(C=O)-, (C₃-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-, (C₃-C₁₀)heteroaryl-NH-(C=O)-, (C₃-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-and (C₁-C₆)alkyl-NH-(C=O)-, (C₃-C₁₀)heterocyclic-NH-(C=O)-, (C₃-C₁₀)cycloalkyl-NH-(C=O)-and (C₁-C₆)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R<sup>3</sup> is optionally substituted by at least one substituent independently selected

T-214 P.016/023 F-871

from  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, halo $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, and  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, And  $(C_1-C_6)$ alkyl, halo,  $H_2N$ -, Ph $(CH_2)_1$ -HN-, PhC<sub>6</sub>)alkylHN-;

s is an integer from one to five;

R<sup>4</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>- $C_6$ )alkyl, ( $C_1$ - $C_6$ )alkyl, ( $C_2$ - $C_6$ )alkenyl, ( $C_2$ - $C_6$ )alkynyl, perhalo( $C_1$ - $C_6$ )alkyl, phenyl, ( $C_5$ -C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-,  $(C_1-C_6)$ alkylHN-,  $(C_1-C_6)$ alkylamino,  $[(C_1-C_6)$ alkyl]<sub>2</sub>-amino,  $(C_1-C_6)$ alkyl-SO<sub>2</sub>-NH-, amino(C=O)-,  $aminoO_2S$ -,  $(C_1-C_6)alkyl-(C=O)-NH$ -,  $(C_1-C_6)alkyl-(C=O)-((C_1-C_6)alkyl)-N$ -. phenyl-(C=O)-NH-, phenyl-(C=O)-(( $C_1$ - $C_6$ )alkyl)-N]-, ( $C_1$ - $C_6$ )alkyl-(C=O)-, phenyl-(C=O)-,  $(C_5-C_{10})$ heteroaryl-(C=O)-,  $(C_5-C_{10})$ heterocyclic-(C=O)-,  $(C_3-C_{10})$ cycloalkyl-(C=O)-,  $(C_5-C_{10})$ heteroaryl-(C=O)-,  $(C_5-C_{10})$ heteroaryl- $(C_5-C_{10})$ heteroaryl-(C=O)-,  $(C_5-C_{10})$ heteroaryl- $(C_5-C_{10})$ heteroary (C=O)-,  $(C_1-C_6)alkyl-O-(C=O)$ -,  $(C_1-C_6)alkyl-NH-(C=O)$ -,  $((C_1-C_6)alkyl)_2-N-(C=O)$ -(C=O)-, phenyl-NH-(C=O)-, phenyl- $((C_1-C_6)aikyl)-N]-(C=O)$ -,  $(C_5-C_{10})heteroaryl-NH-(C=O)$ -,  $(C_5-C_{10})$ heterocyclic-NH-(C=O)-,  $(C_3-C_{10})$ cycloalkyl-NH-(C=O)- and  $(C_1-C_6)$ alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R<sup>4</sup> is optionally substituted by at least one substituent independently selected from the group consisting of (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, halo, H2N-,  $Ph(CH_2)_{1-6}HN-$ ,  $(C_1-C_6)alkylHN-$ ,  $(C_5-C_{10})heteroaryl$  and  $(C_5-C_{10})heterocyclyl$ ;

with the proviso that when R4 is a substituted phenyl moiety, then (a) R1 is not naphthyl, phenyl or anthracenyl and (b) if R1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms independently selected from N, O and S, then the fused cyclic ring of said R<sup>1</sup> moiety is substituted.

19. (currently amended) A compound selected from the groups consisting of 2-(4-Benze[1,3]dioxol 5-yl-oxazol 5-yl)-6-methyl pyridine: 4 [5 (6 Methyl-pyridin-2-yl) exazel 4 yl] quinoline: 1 Methyl-6-[5-(6-methyl-pyridin 2 yl) exazel-4-yl]-1H-benzetriazele: 2 Methyl 5 [5 (6 methyl pyridin 2 yl) exazel 4-yl] 2H benzetriazele;

7346222928

```
6 [5 (6 Methyl pyridin 2 yl) exazel 4-yl] quineline;
```

6-[5 (6 Mothyl-pyridin 2 yl) exazol 4 yl] quinexaline;

PATENT PFIZER ANN ARBOR MI

- 2 [5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;
- 4 f5 (6 Methyl-pyridin 2 yl) exazel 4 yl] pyridin 2 yl}-phenyl-amine;
- 2-(4-Benze[1,3]dioxel 5-yl 2 methyl-exazel 5-yl) 6 methyl pyridine;
- 1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl) exazel 4 yl] 1H benzotriazole;
- 2 Methyl 5-[2 methyl-5-(6-methyl-pyridin-2-yl)-oxazol 4-yl] 2H benzotriazole;
- 6 [2 Methyl 5 (6 methyl pyridin 2 yl) exazel 4-yl]-quinoline;
- 6 [2 Methyl 5 (6 methyl pyridin 2 yl) exazel 4 yl] quinoxaline;
- 2-[2-Mothyl-5-(6-mothyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;
- [4 [2 Methyl-5 (6-methyl-pyridin-2-yl) oxazol 4-yl] pyridin 2-yl} phonyl-amine;
- 4 [2 Methyl 5 (6 methyl pyridin 2 yl) exazol-4-yl]-quinoline;
- 4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 4-(3-Methyl-3H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
- 5-(6-Methyl-pyridin-2-yl)-4-quinolin-6-yl-thiazol-2-ylamine;
- 5-(6-Methyl-pyridin-2-yl)-4-quinoxalin-6-yl-thiazol-2-ylamine;
- {4-[2-Amino-5-(6-mothyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phonyl-amino;
- 1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;
- 2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;
- 2-(4-Benzo[1,3]dioxol-5-yl-thiazol-5-yl)-6-methyl-pyridine;
- 6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;
- 2-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;
- {4 [5 (6 Methyl pyridin 2 yl)-thiazol-4-yl}-pyridin 2 yl}-phenyl-amine;
- 4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;
- 6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;
- 1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;
- 2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;
- 2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-5-yl)-6-methyl-pyridine;
- 6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxalino;

- 2-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thia2ol-4-yl]-[1,5]naphthyridine;
- {4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazel-4-yl]-pyridin-2-yl}-phonyl-amine;
- 4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline; and
- 6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline; or a pharmaceutically acceptable salt thereof.

## 20. (canceled)

- 21. (currently amended) A compound selected from the groups consisting of
  - 1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;
  - 2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;
  - 2-(5-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-6-methyl-pyridine;
  - 6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;
  - 2-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;
  - {4 [4 (6 Methyl pyridin 2 yl)-thiazol-5-yl]-pyridin 2 yl} phenyl amine;
  - 4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
  - 6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;
  - 1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;
  - 2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;
  - 2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-4-yl)-6-methyl-pyridine:
  - 6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;
  - 2-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;
  - [4 [2 methyl-4 (6-Methyl-pyridin-2-yl) thiazol 5 yl] pyridin-2-yl} phonyl amine:
  - 4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline; and
- 6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline; or a pharmaceutically acceptable salt thereof.
- 22. (currently amended) A compound selected from the groups consisting of
  - 5-(3-Methyl-3H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;
  - 5-(2-Methyl-2H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamino;

-18-

- 5-Benzo[1,3]dioxol-5-yl-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine; and
- 4-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-thiazol-2-ylamine; or a pharmaceutically acceptable salt thereof.